A STEP ahead for CAR-T cell therapy of large B cell lymphoma: understanding the molecular determinants of resistance

Translational Cancer Research, Год журнала: 2023, Номер 12(11), С. 2970 - 2975

Опубликована: Ноя. 1, 2023

Язык: Английский

---

The future of whole genome sequencing in pediatrics

Liječnički vjesnik, Год журнала: 2023, Номер 145(Supp 5)

Опубликована: Окт. 10, 2023

Язык: Английский

---

Editorial: Liquid biopsies in hematological malignancies

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Июнь 12, 2024

Keywords: liquid biopsies, hematological malignancies, minimal residual disease (MRD), immunotherapy, next-generation sequence (NGS)

Язык: Английский

---

Emerging Significance and Clinical Application of Liquid Biopsy in Early Diagnosis and Monitoring of Cancer

Journal of the Scientific Society, Год журнала: 2024, Номер 51(2), С. 123 - 124

Опубликована: Апрель 1, 2024

Precision medicine in the field of cancer management continues to evolve, and so do challenges demands regarding diagnosis, prognosis, prediction treatment resistance.[1] The discovery molecular agents that can target specific genomic changes metastatic patients has revolutionized patient care.[2] tumor heterogeneity remains a daunting obstacle for clinicians who need optimize therapy regimens based on an individual's genome.[3] Tissue biopsies, which still currently represent gold standard unfortunately only reflect single point time site tumor. Such sampling method is, thus, inadequate comprehensive characterization patient's tumor, as it been demonstrated various areas within primary or metastases fact harbor different profiles.[4] Furthermore, procedure is invasive causes discomfort when opt repeat biopsy. Liquid biopsy innovative, minimally technique gained significant attention recent years its potential monitoring.[5] Unlike traditional tissue require surgical procedures obtain samples, liquid biopsies analyze circulating cells (CTCs), cell-free DNA (cfDNA), exosomes, other biomarkers body fluids such blood, urine, saliva.[6] Thus, utility provides deeper insights into biology improves care. Emerging Significance are less compared reducing risks associated with procedures. detect cancer-related mutations alterations cfDNA CTCs even at early stages, potentially before symptoms appear.[4-6] This enables earlier intervention better prognosis. allow continuous monitoring dynamics response. crucial adjusting therapeutic strategies promptly also provide more overview since they capture genetic information from multiple sites metastases, might be missed single-site biopsy.[6] minimal risk, making suitable repeated sampling. particularly beneficial tracking disease progression resistance over time. Benefits Biopsy Early Diagnosis Monitoring Cancer emerged transformative tool diagnosis cancer, leveraging noninvasive nature ability profiles fluids.[7] help cancer-specific methylation patterns stages disease. Technologies next-generation sequencing digital polymerase chain reaction used identify these high sensitivity. presence bloodstream signal existence early-stage tumor.[5-7] Advances microfluidics immunoaffinity techniques have improved isolate characterize CTCs. screen individuals risk those family history predispositions (e.g., BRCA1/2 breast cancer). proactive approach lead detection intervention.[7] For presenting nonspecific symptoms, by identifying tumor-associated epigenetic changes, diagnostic initially. By analyzing points, real-time how responding treatment. timely decisions about continuing, changing, stopping changes.[8] assessing relapse deciding additional strategies. Tumors often develop treatments. new confer resistance, allowing adjustment regimens. Continuous levels track time.[5-7] These longitudinal data valuable understanding evolution adapting plans accordingly. Quantitative analysis serve prognostic indicators. Higher poorer outcomes, guiding intensity type required. will reduce leading lower discomfort.[8] allows regular monitor captures wide range providing complete picture heterogeneity, quicker results biopsy, aiding clinical decision- making.[9] Clinical Applications being developed cancers lung, breast, colorectal, prostate cancers. Tests like fragments patterns. They actionable alterations, selection targeted therapies personalized plans.[7,8] example, epidermal growth factor receptor (EGFR) lung inform use tyrosine kinase inhibitors. burden residual measuring biomarkers, assess effectiveness make adjustments necessary.[8] enhance identification ongoing therapies, switch alternative instance, secondary EGFR gene indicate first-line Biomarkers detected through information, helping predict outcomes.[2,3] quantity correlate overall survival. helps clinician appropriate decide extent timing interventions spread. Challenges, Consideration, Future Directions represents advancement oncology, offering invasive, comprehensive, dynamic management. As research technology continue expected play increasingly central role precision medicine, transforming care, improving outcomes.[9] Despite potential, faces several challenges. Ensuring accuracy detecting low-abundance amid background normal sensitivity specificity critical, low concentrations tumor-derived materials difficult.[9,10] Developing standardized protocols sample collection, processing, necessary ensure reproducibility reliability across settings. Extensive trials validate efficacy types stages.[10] Comprehensive regulatory approvals required cost-effectiveness tests. Educating health-care providers integrating existing workflows essential widespread adoption. Its real-time, makes powerful fight against cancer.[11] technologies advance validations continue, become integral part detection, decisions, ultimately enhancing outcomes. Financial support sponsorship Nil. Conflicts interest There no conflicts interest.

Язык: Английский

---

Novel Immunological Markers of Intestinal Impairment Indicative of HIV-1 Status and/or Subclinical Atherosclerosis

bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Ноя. 25, 2024

ABSTRACT Antiretroviral therapy (ART) controls HIV-1 replication in people with (PWH), but immunological restauration at mucosal barrier surfaces is not achieved. This fuels microbial translocation, chronic immune activation, and increased comorbidities, including cardiovascular disease (CVD). Here, we sought to identify novel markers of impairment the blood predict HIV and/or CVD status. Flow cytometry was used characterize CD326/EpCAM + intestinal epithelial cells (IEC); CD4 T-cells; CD8 intraepithelial lymphocytes (IELs); subsets T-cells expressing Th17 (CCR6) gut-homing (Itgβ7) markers. To this aim, collected peripheral mononuclear (PBMCs) from 42 ART-treated PWH (HIV ) 40 uninfected participants - Canadian Aging Cohort Study (CHACS). Both groups were categorized based on presence coronary atherosclerotic plaques measured by CT scan angiography as total plaque volume (TPV, mm 3 ). Our findings associate status frequencies circulating CD326 IEC; activated (CD69 HLA-DR (ItgαE CCR6 CCR9 phenotypes, Itgβ7 decreased IELs. Logistic regression analyses confirmed predictive capacity above cellular regarding Spearman correlation revealed a positive between TPV T-cell frequencies.Together, these results highlighted significant dysregulation persistent alterations despite effective viral suppression ART linked abundance burden. Thus, strategies targeting gut-immune axis restoration may reduce onset improve long-term health outcomes PWH.

Язык: Английский

---

Mutational heterogeneity in large B-cell lymphoma: insights from paired biopsies

Annals of Hematology, Год журнала: 2024, Номер unknown

Опубликована: Дек. 7, 2024

Язык: Английский

---